Literature DB >> 15337502

Reversal of hyperglycemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats.

Renu A Kowluru1, Saiyeda N Abbas, Sarah Odenbach.   

Abstract

Studies have shown that good metabolic control (GC) is beneficial in slowing the progression of nephropathy in diabetes, and if the duration of poor metabolic control (PC) is prolonged before reinstitution of GC, nephropathy is not easily reversed. This study is to identify the biochemical abnormalities that could contribute to the resistance of nephropathy to reverse after establishment of GC in rats. The effect of reinstitution of GC and its duration is evaluated on oxidative stress and nitric oxide (NO) levels in the renal cortex and urine of diabetic rats. The rats were maintained in GC (5% glycated hemoglobin, GHb) soon after or 6 months after induction of hyperglycemia, and were sacrificed 13 months after induction of diabetes. For rats in which GC was initiated soon after induction of diabetes, oxidative stress [as measured by the levels of lipid peroxides (LPOs), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and reduced glutathione (GSH)] and NO in urine and renal cortex were not different from that observed in normal control rats, but when reinstitution of GC was delayed for 6 months after induction of diabetes, oxidative stress and NO remain elevated in both urine and renal cortex. This suggests that hyperglycemia-induced oxidative stress and NO can be prevented if GC is initiated very early, but are not easily reversed if PC is maintained for longer durations. Understanding the mechanisms responsible for this phenomenon could reveal novel means to reverse nephropathy in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337502     DOI: 10.1016/j.jdiacomp.2004.03.002

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  36 in total

Review 1.  Epigenetic Mechanisms in Diabetic Kidney Disease.

Authors:  Merlin C Thomas
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

Review 2.  Understanding Metabolic Memory: A Tale of Two Studies.

Authors:  Rachel G Miller; Trevor J Orchard
Journal:  Diabetes       Date:  2020-03       Impact factor: 9.461

Review 3.  Epigenetic modifications in the pathogenesis of diabetic nephropathy.

Authors:  Marpadga A Reddy; Jung Tak Park; Rama Natarajan
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

4.  Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

5.  Epigenetics of diabetic complications.

Authors:  Louisa M Villeneuve; Rama Natarajan
Journal:  Expert Rev Endocrinol Metab       Date:  2010-01

6.  Beneficial effect of myricetin on renal functions in streptozotocin-induced diabetes.

Authors:  Filiz Ozcan; Asli Ozmen; Bahar Akkaya; Yakup Aliciguzel; Mutay Aslan
Journal:  Clin Exp Med       Date:  2011-11-15       Impact factor: 3.984

Review 7.  Epigenetic mechanisms in diabetic complications and metabolic memory.

Authors:  Marpadga A Reddy; Erli Zhang; Rama Natarajan
Journal:  Diabetologia       Date:  2014-12-07       Impact factor: 10.122

Review 8.  Hyperglycemia and vascular metabolic memory: truth or fiction?

Authors:  Cristina Bianchi; Roberto Miccoli; Stefano Del Prato
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

9.  Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis.

Authors:  Gul N Shah; Tulin O Price; William A Banks; Yoichi Morofuji; Andrej Kovac; Nuran Ercal; Christine M Sorenson; Eui S Shin; Nader Sheibani
Journal:  J Pharmacol Exp Ther       Date:  2012-12-17       Impact factor: 4.030

Review 10.  Antioxidant anti-inflammatory treatment in type 2 diabetes.

Authors:  Antonio Ceriello; Roberto Testa
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.